Insilico Medicine Taiwan Limited
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Insilico’s flagship suite includes PandaOmics (multi-omics target identification), Chemistry42 (de novo molecular design), and InClinico (clinical outcome prediction). By leveraging these AI modules, they can rapidly generate novel molecules, predict safe
Founded Year
2018
Unified Business No.
50759371
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Insilico Medicine is a global, AI‑driven biotech company focused on generative AI for drug discovery. With headquarters in the U.S. and research facilities in Hong Kong, Taiwan, and Europe, their mission is to revolutionize drug development using their proprietary Pharma.AI platform across biology, chemistry, and clinical stages.
